Corvus Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Corvus Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-81.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 80% of Healthcare companies in United States.
Cash Cushion Ratio
+6%Cash, after subtracting all debt, equals 6% of its market value (net cash).
Lower than 55% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Corvus Pharmaceuticals, Inc. made a loss over the last year. Corvus Pharmaceuticals, Inc. owes $0.06 for every $1 it owns. Corvus Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCorvus Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.98The share price is 3.98 times Corvus Pharmaceuticals, Inc.'s book value per share, higher than 65% of Healthcare companies in United States.
Market cap
$896 MThe total market value of all of Corvus Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 62% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$225 MWhat Corvus Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.68Net worth divided by the number of shares. The share price of $10.65 is 4.0 times this, which is the P/B above.
Return on equity (ROE)
-35.4%Corvus Pharmaceuticals, Inc. lost 35.4% of its shareholders' money over the last year, higher than 58% of Healthcare companies in United States.
Owes vs Owns
0.06×Corvus Pharmaceuticals, Inc. owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Dividend yield
NoneCorvus Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossCorvus Pharmaceuticals, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashCorvus Pharmaceuticals, Inc. held $56 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Corvus Pharmaceuticals, Inc.: $896 M ÷ $225 M (30 Jun 2026) = 4.0.
What is Corvus Pharmaceuticals, Inc.'s return on equity?
Corvus Pharmaceuticals, Inc. lost 35.4% of its shareholders' money over the last year, higher than 58% of Healthcare companies in United States.
How much does Corvus Pharmaceuticals, Inc. owe compared with what it owns?
Corvus Pharmaceuticals, Inc. owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Does Corvus Pharmaceuticals, Inc. pay a dividend?
No. Corvus Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.